1
/
of
0
Docetero (Docetaxel)
Docetero (Docetaxel)
Regular price
₱3,150.00 PHP
Regular price
Sale price
₱3,150.00 PHP
Taxes included.
Quantity
Couldn't load pickup availability
Docetero (Docetaxel) – Advanced Chemotherapy for Multiple Cancer Types
Docetaxel is a clinically proven chemotherapy medication belonging to the taxane class of antimitotic agents. It is prescribed to treat breast cancer, ovarian cancer, prostate cancer, stomach cancer, non-small-cell lung cancer (NSCLC), and head and neck cancers. As a semisynthetic analogue of paclitaxel, docetaxel offers enhanced efficacy in cancer cell suppression and is widely recognized in oncology practice.
Mechanism of Action
Docetaxel works by binding to microtubules at a 1:1 molecular ratio, stabilizing their structure and preventing depolymerization. This interference with microtubule dynamics halts cell division and triggers programmed cancer cell death. Studies demonstrate that docetaxel is approximately twice as potent as paclitaxel in inhibiting microtubule breakdown, making it a preferred choice in many treatment regimens. The drug does not bind to dimeric tubulin, distinguishing its mechanism from other chemotherapy agents.
Administration and Treatment Approach
Docetaxel is administered as a slow intravenous infusion under medical supervision. It may be used as a single-agent therapy or combined with other anticancer medications to optimize treatment outcomes. Dosing and frequency are determined by oncologists based on individual patient factors, cancer stage, and treatment protocols.
Expected Side Effects and Safety Considerations
Common side effects include alopecia (hair loss), cytopenia (low blood cell counts), myalgia (muscle pain), nausea, vomiting, fatigue, and peripheral neuropathy (numbness or tingling). More serious adverse effects may include hepatotoxicity (liver damage), hypersensitivity reactions, fluid retention, neutropenic colitis, and pneumotoxicity. Patients with hepatic impairment may experience intensified adverse effects and require dose adjustments.
Docetaxel is contraindicated in pregnancy due to documented fetal harm. Regular monitoring during treatment is essential to detect and manage serious complications promptly. Healthcare providers assess individual risk-benefit profiles before initiating therapy and maintain vigilant surveillance throughout the treatment course.
Docetaxel is a clinically proven chemotherapy medication belonging to the taxane class of antimitotic agents. It is prescribed to treat breast cancer, ovarian cancer, prostate cancer, stomach cancer, non-small-cell lung cancer (NSCLC), and head and neck cancers. As a semisynthetic analogue of paclitaxel, docetaxel offers enhanced efficacy in cancer cell suppression and is widely recognized in oncology practice.
Mechanism of Action
Docetaxel works by binding to microtubules at a 1:1 molecular ratio, stabilizing their structure and preventing depolymerization. This interference with microtubule dynamics halts cell division and triggers programmed cancer cell death. Studies demonstrate that docetaxel is approximately twice as potent as paclitaxel in inhibiting microtubule breakdown, making it a preferred choice in many treatment regimens. The drug does not bind to dimeric tubulin, distinguishing its mechanism from other chemotherapy agents.
Administration and Treatment Approach
Docetaxel is administered as a slow intravenous infusion under medical supervision. It may be used as a single-agent therapy or combined with other anticancer medications to optimize treatment outcomes. Dosing and frequency are determined by oncologists based on individual patient factors, cancer stage, and treatment protocols.
Expected Side Effects and Safety Considerations
Common side effects include alopecia (hair loss), cytopenia (low blood cell counts), myalgia (muscle pain), nausea, vomiting, fatigue, and peripheral neuropathy (numbness or tingling). More serious adverse effects may include hepatotoxicity (liver damage), hypersensitivity reactions, fluid retention, neutropenic colitis, and pneumotoxicity. Patients with hepatic impairment may experience intensified adverse effects and require dose adjustments.
Docetaxel is contraindicated in pregnancy due to documented fetal harm. Regular monitoring during treatment is essential to detect and manage serious complications promptly. Healthcare providers assess individual risk-benefit profiles before initiating therapy and maintain vigilant surveillance throughout the treatment course.